Data reported at the 2022 Annual Meeting of the American Society for Clinical OncologyNBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination w.
Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care
SEATTLE, Jan. 27, 2022 Atossa Therapeutics, Inc. , a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and.